The CBD Jaw-Pain Regimen Included Holding Oil Under the Tongue and Swallowing

Participants in the CBD jaw-pain trial held the oil under the tongue for sixty seconds and then swallowed it. That procedure defines the tested regimen more precisely than calling it simply oral or sublingual CBD.

Administration involved two stages

The active regimen supplied 20 mg CBD daily in 1 mL of oil over three months. The comparator was 1 mL hemp seed oil without detectable CBD. The study concerned myofascial pain in the muscles used for chewing.

Holding oil in the mouth followed by swallowing does not reveal what proportion of the administered CBD entered through the oral mucosa and what proportion was absorbed after swallowing. The trial did not measure plasma CBD to resolve that question.

A route label cannot supply a measured exposure

The clinical outcomes were patient-reported pain and jaw-function scores. No statistically significant between-group pain advantage was demonstrated at the reported follow-ups, and jaw-function improvement in both groups did not establish CBD superiority.

It would be unsupported to turn this clinical result into a specific blood concentration, absorption percentage or finding of inadequate exposure. It would also be unsupported to assume that another oil, holding time or swallowed formulation would necessarily produce an identical result.

Describe the regimen before generalizing

A useful treatment claim states the dose, oil formulation, holding-and-swallowing procedure, diagnosis and comparator. These details preserve the trial’s scope without changing its null between-group result. The small single-center study, adherence limitations and commercial support also belong in an appraisal. This was human clinical research, not an animal experiment or an impairment test.

Related analysis: the CBD jaw-pain trial’s pain and function results.

Research cited

Reeve and colleagues (2026), Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial. DOI: 10.1159/000551040.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

The HGN Comparison Did Not Validate a Standalone Cannabis Impairment Test

The HGN analysis compared small groups defined by self-reported duration. It did not establish a standalone diagnostic accuracy for identifying cannabis-impaired drivers. What the statistical comparison involved Forty-four participants underwent horizontal gaze nystagmus assessment, with forty-three examined at three hours after smoking. The paper compared HGN incidence at that time…

Spread the love

Read Article: The HGN Comparison Did Not Validate a Standalone Cannabis Impairment Test

Stratified Cannabis Duration Patterns Coexisted With a Null Overall Correlation

The paper described an inverse pattern after grouping participants by self-reported duration, while its unstratified correlation between baseline blood THC and duration was nonsignificant. Both findings belong in an accurate account. The two analyses asked related questions differently Baseline blood measurements were available for sixty-four participants. The authors divided participants…

Spread the love

Read Article: Stratified Cannabis Duration Patterns Coexisted With a Null Overall Correlation

Percent-of-Maximum Cannabis Ratings Did Not Compare Absolute Severity

The paper’s average percent-of-maximum curve normalized each participant to that person’s own highest self-rating. Equal percentages on that graph did not necessarily mean equal absolute symptom severity across participants. The denominator was personal Wurz and DeGregorio summarized self-assessments from seventy-four participants after cannabis smoking. Each person’s ratings were expressed relative…

Spread the love

Read Article: Percent-of-Maximum Cannabis Ratings Did Not Compare Absolute Severity

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us